Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Is It Possible to Omit Bone Marrow Biopsy in Diagnostic Workup in Patients with Newly Diagnosed Primary CNS Lymphoma? a Retrospective Analysis in the PET/CT Era

Jelena Jelicic, Dennis Lund Hansen, Sarah Sand Carlsen, Michael Thorsgaard, Ditte Hersby, Karina Kannik, Amalie Emilie Munksgaard, Thomas S. Larsen, Karen Juul-Jensen

Blood (2022) 140 (Supplement 1): 1334–1335.

https://doi.org/10.1182/blood-2022-165416

Published: 2022

Journal Articles

Level of Unique T-Cell Clonotypes Are Associated with Clonal Hematopoiesis and Survival in Patients with Lymphoma Intended for Autologous Stem Cell Transplant

Simon Husby, Gustav Ørting Jørgensen, Francesco Favero, Jakob Schmidt Jespersen, German G.R. Gonzalez, Christian Nielsen, Betina Sørensen, Lene Hyldahl Ebbesen, John Bæch, Eva Kannik Hastrup, Pär L. Josefsson, Michael Thorsgaard, Tarec Christoffer El-Galaly, Peter de Nully Brown, Thomas Stauffer Larsen, Joachim Weisenfeldt, Kirsten Grønbæk

Blood (2021) 138 (Supplement 1): 3942.

https://doi.org/10.1182/blood-2021-145417

Published: 2021

Journal Articles

Patients with Primary Central Nervous System Lymphoma Have High Levels of Soluble Programmed Cell Death Protein 1 in Their Pretherapeutic Cerebrospinal Fluid

Rasmus Svane Ditlev Severinsen, Marie Beck Enemark, Julie Bondgaard Mortensen, Eigil Kjeldsen, Michael Thorsgaard, Elisa Jacobsen Pulczynski, Gorm von Oettingen, Holger Jon Møller, Christopher Vejgaard, Mette Bjerre, Francesco d'Amore

Blood (2021) 138 (Supplement 1): 1334.

https://doi.org/10.1182/blood-2021-144882

Published: 2021

Journal Articles

Clinical Impact of Clonal Hematopoiesis after Autologous Stem Cell Transplantation for Lymphoma: A National Population-Based Cohort Study

Blood (2018) 132 (Supplement 1): 607.

https://doi.org/10.1182/blood-2018-99-109893

Published: 2018

Journal Articles

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Michael Roost Clausen, MD, Sirpa Leppa, MD, Peter de Nully Brown, MD, Jette Soenderskov Goerloev, MD, Michael Panny, MD, Wolfgang Willenbacher, MD, Ida Blok Sillesen, MD, Erik Segel, MD, Hans Bentzen, MD, Michael Thorsgaard, MD, Elisa Jacobsen Pulczynski, MD, Peter Kamper, MD, Lars C. Gormsen, MD, Julie Mortensen, MDcal Student, Grethe Lauritzsen, MD, Thomas Relander, MD PhD, Francesco d'Amore, MD PhD

Blood (2016) 128 (22): 1782.

https://doi.org/10.1182/blood.V128.22.1782.1782

Published: 2016

Journal Articles

Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas

Francesco d'Amore, Judit Joergensen, Ida Blok Sillesen, Erik Segel, Hans Bentzen, Michael Thorsgaard, Elisa Jacobsen Pulczynski, Bjarne Bach Pedersen, Dorte Gillström, Michael Clausen, Peter Kamper, Trine Silkjaer, Lars C. Gormsen, Sirpa Leppä, Helle Toldbod

Blood (2014) 124 (21): 5435.

https://doi.org/10.1182/blood.V124.21.5435.5435

Published: 2014

NARROW

Is It Possible to Omit Bone Marrow Biopsy in Diagnostic Workup in Patients with Newly Diagnosed Primary CNS Lymphoma? a Retrospective Analysis in the PET/CT Era

Level of Unique T-Cell Clonotypes Are Associated with Clonal Hematopoiesis and Survival in Patients with Lymphoma Intended for Autologous Stem Cell Transplant

Patients with Primary Central Nervous System Lymphoma Have High Levels of Soluble Programmed Cell Death Protein 1 in Their Pretherapeutic Cerebrospinal Fluid

Clinical Impact of Clonal Hematopoiesis after Autologous Stem Cell Transplantation for Lymphoma: A National Population-Based Cohort Study

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Is It Possible to Omit Bone Marrow Biopsy in Diagnostic Workup in Patients with Newly Diagnosed Primary CNS Lymphoma? a Retrospective Analysis in the PET/CT Era

Level of Unique T-Cell Clonotypes Are Associated with Clonal Hematopoiesis and Survival in Patients with Lymphoma Intended for Autologous Stem Cell Transplant

Patients with Primary Central Nervous System Lymphoma Have High Levels of Soluble Programmed Cell Death Protein 1 in Their Pretherapeutic Cerebrospinal Fluid

Clinical Impact of Clonal Hematopoiesis after Autologous Stem Cell Transplantation for Lymphoma: A National Population-Based Cohort Study

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only